• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Mumbai, Sept. 10 Additional time has been sought by the Government to submit its arguments to the Madras High Court on the appointment of Mr Chandrasekaran as a technical member on the Intellectual Property Appellate Board (IPAB).

The next hearing is on October 8.

The IPAB was to look into the rejection of Swiss drug-maker Novartis’ application for its cancer drug Glivec by the Patent Controller. And Novartis had objected to the appointment of Mr Chandrasekaran on the IPAB, as he was the head of the Patent Controller’s office when it had rejected Novartis’ application in January 2006.

The Centre will have to communicate its stand on the appointment of the technical member to the Court, else it will be left to the Court to decide, said a lawyer familiar with the development.

Explaining why Novartis had opposed the appointment of the former Patent Controller General as a technical member on the IPAB, the company said: “We expect the opportunity to explain our case clearly to an objective board. Because the current technical member of the appellate board was responsible for the original rejection of the Glivec patent, and was a party in the patent appeal in the High Court, we believe he cannot act as an impartial member of the Appellate Board,” a company statement said.

Only last month, the Madras High Court had dismissed another case regarding Novartis’ Glivec. The drug major had contested, in a separate case, certain constitutional parameters that had contributed to the rejection of Novartis’ patent application by the Patent Controller.

More Stories on : Pharmaceuticals | Courts/Legal Issues | IPR

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Axis Bank, Europe bank in pact

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line